Laying Out USP Resources & Standards to Support Assessment of ADC Quality Attributes - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Laying Out USP Resources & Standards to Support Assessment of ADC Quality Attributes

12:00 pm - Monday 12th October 2026

Contextualizing existing resources and standards supporting mAbs and small molecule aspects of ADCs
Exploring development of an ADC mimic reference material to support CQA assessment of ADC therapeutics
Understanding the need for additional, future ADC guidance to support quality control and standards from development to commercialization

Speakers:

Niomi Peckham

Niomi Peckham

Global Director, Pipeline Development, Biologics

U.S. Pharmacopeia